2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management CLINICAL STATEMENTS AND GUIDELINES of heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282 93. S5.2-2. Committees for Cardiac insufficiency Bisoprolol Study II. The car- diac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9 13. S5.2-3. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303 10. S5.2-4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart fail- ure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349 55. S5.2-5. Dargie HJ. Effect of carvedilol on outcome after myocardial infarc- tion in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385 90. S5.2-6. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldo- sterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309 21. S5.2-7. Al Chekakie MO. Traditional heart failure medications and sudden cardiac death prevention: a review. J Cardiovasc Pharmacol Ther. 2013;18:412 26. S5.2-8. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, cap- topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893 906. S5.2-9. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospital- izations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in conges- tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295 302. S5.2-10. 